A Randomized Controlled Trial for Prevention of Postoperative Nausea and Vomiting after Laparoscopic Sleeve Gastrectomy: Aprepitant/Dexamethasone vs. Mirtazapine/Dexamethasone
Table 1
Baseline characteristics among the studied groups.
Variables
A/D group (N = 29)
M/D group (N = 28)
D group (N = 29)
value
Age (years)
40.6 (6.1)
39.1 (7.3)
41.5 (6.0)
^0.391
BMI (kg.m−2)
47.0 (2.1)
46.8 (2.7)
47.2 (2.3)
^0.836
Sex, M/F
16/13
17/11
19/10
#0.722
Associated comorbidities
Medically free
13
11
13
#0.888
HTN or DM
16
17
16
Smoking, n (%)
12 (41.4)
16 (57.1)
14 (48.3)
#0.491
History of motion sickness, n (%)
4 (13.8)
2 (7.1)
5 (17.2)
§0.609
History of PONV, n (%)
3 (10.3)
2 (7.1)
4 (13.8)
§0.905
Operation duration (min)
103.1 (7.3)
101.9 (5.4)
102.9 (6.8)
^0.761
Intraoperative fluids (ml)
1081.0 (114.5)
1098.2 (76.4)
1070.7 (100.5)
^0.571
The values are presented as mean ± SD, number of patients (%), or median (Q1, Q3). ^ANOVA test. #Chi-square test. §Fisher’s exact test. A/D group: aprepitant/dexamethasone group, M/D group: mirtazapine/dexamethasone group, D group: dexamethasone group, HTN: hypertension, DM: diabetes mellitus, and PONV: postoperative nausea and vomiting.
